Rhythm Pharmaceuticals, INC Form 4 insider transactions

Director Edward T. Mathers reports the exercise of stock options and vesting of restricted stock units in Rhythm Pharmaceuticals.

Director Camille L. Bedrosian reports the vesting of 3,000 restricted stock units into common stock of Rhythm Pharmaceuticals.

Director Christophe Jean exercised options to acquire 3,000 shares of Rhythm Pharmaceuticals common stock on June 21, 2024.

Director Jennifer L. Good reported the vesting of 3,000 restricted stock units into common stock of Rhythm Pharmaceuticals on June 21, 2024.

Director Lynn A. Tetrault reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Director David W.J. McGirr acquired 14,000 stock options and 4,000 restricted stock units in Rhythm Pharmaceuticals, according to a Form 4 filing.

Director Edward T. Mathers acquired stock options and restricted stock units in Rhythm Pharmaceuticals, according to a recent SEC filing.

Director Jean Christophe acquired 14,000 stock options and 4,000 restricted stock units in Rhythm Pharmaceuticals, Inc.

Director Camille L. Bedrosian reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Director Jennifer L. Good reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Director Stuart A. Arbuckle reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reports the exercise of stock options and subsequent sale of shares on May 9, 2024.

EVP Yann Mazabraud reports transactions involving Rhythm Pharmaceuticals' stock, including the vesting and disposal of restricted stock units, as well as the acquisition of new units.

Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, sold 368 shares of common stock on April 2, 2024, to cover withholding taxes related to vested restricted stock units.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, sold 18,235 shares of common stock on March 21, 2024, to cover withholding taxes related to vesting restricted stock units.

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold shares of common stock on March 20, 2024, to cover withholding taxes related to vesting restricted stock units.

Hunter Smith, CFO of Rhythm Pharmaceuticals, sold 15,515 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, sold 15,515 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Rhythm Pharmaceuticals CEO David Meeker sold 45,494 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

EVP, Head of International at Rhythm Pharmaceuticals, Yann Mazabraud, sold 16,000 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold 15,515 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, sold 15,515 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.